⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26394048 | 1.00 | L3MBTL3 (0.50) | — | |
| SCHEMBL26111928 | 1.00 | L3MBTL3 (0.50) | — | |
| SCHEMBL20756261 | 1.00 | L3MBTL3 (0.50) | — | |
| SCHEMBL3313037 | 1.00 | — | — | |
| SCHEMBL26109078 | 1.00 | L3MBTL3 (0.50) | — | |
| Ammonia Solution, Strong SCHEMBL28863163 | 0.97 | CYP2D6 (0.48) | — | |
| Iodide SCHEMBL26113492 | 0.97 | CYP2D6 (0.48) | — | |
| Iodide SCHEMBL26113494 | 0.97 | CYP2D6 (0.48) | — | |
| SCHEMBL26112589 | 0.96 | L3MBTL3 (0.52) | — | |
| SCHEMBL26117153 | 0.96 | L3MBTL3 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 204 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025124516-A1 | COMPOUND HAVING AKT KINASE-DEGRADING ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 南京正大天晴制药有限公司 | 2025-06-19 | — | — | WO | claimed |
| CN-118459466-A | Triazolopyrimidinone derivative and application thereof in medicine | 西藏海思科制药有限公司 | 2024-08-09 | — | — | CN | claimed |
| CN-118339151-A | Compound for inhibiting or degrading BRD9, composition and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-07-12 | — | — | CN | claimed |
| CN-118063435-A | Piperidine-2, 6-dione derivative and application thereof | 西藏海思科制药有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-116554147-A | Pyrazole derivative, composition and pharmaceutical application thereof | 四川海思科制药有限公司 | 2023-08-08 | — | — | CN | claimed |
| WO-2023143384-A1 | COMPOUND FOR INHIBITING OR DEGRADING HPK1 KINASE AND MEDICAL USE THEREOF | 四川海思科制药有限公司 | 2023-08-03 | — | — | WO | claimed |
| CN-116375742-A | Azaaromatic ring derivative, composition and pharmaceutical application thereof | 海思科医药集团股份有限公司 | 2023-07-04 | — | — | CN | claimed |
| WO-2023109892-A1 | COMPOUND FOR INHIBITING OR DEGRADING BRD9, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 海思科医药集团股份有限公司 | 2023-06-22 | — | — | WO | claimed |
| CN-116253717-A | Pyridazine derivative and application thereof in medicine | 海思科医药集团股份有限公司 | 2023-06-13 | — | — | CN | claimed |
| CN-116134028-A | Compound capable of degrading BTK kinase, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2023-05-16 | — | — | CN | claimed |
| CN-114920690-A | Amide derivative and application thereof in medicine | 四川海思科制药有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-114805199-A | Benzene ring derivative and application thereof in medicine | 海思科医药集团股份有限公司 | 2022-07-29 | — | — | CN | claimed |
| WO-2022111526-A1 | BENZENE RING DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 四川海思科制药有限公司 | 2022-06-02 | — | — | WO | claimed |
| EP-2720544-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | Merck Sharp & Dohme Corp. (US) | 2014-04-23 | — | — | EP | claimed |
| WO-2012173917-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS, AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2012-12-20 | — | — | WO | claimed |
| EP-1851199-B1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | AVENTIS PHARMA INC (US) | 2012-05-16 | — | — | EP | claimed |
| US-20070265309-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | claimed |
| EP-1851199-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | Aventis Pharmaceuticals, Inc. (US) | 2007-11-07 | — | — | EP | claimed |
| WO-2006086705-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-17 | — | — | WO | claimed |
| US-12600726-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2026-04-14 | — | — | US | disclosed |
| US-12600726-B2 | Antagonists of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2026-04-14 | — | — | US | disclosed |
| US-20250302845-A1 | SELECTIVE DOPAMINE INCREASE | SOBRERA PHARMA AB (SE) | 2025-10-02 | — | — | US | disclosed |
| US-RE50554-E1 | Amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250206724-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2025-06-26 | — | — | US | disclosed |
| WO-2025124516-A1 | COMPOUND HAVING AKT KINASE-DEGRADING ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 南京正大天晴制药有限公司 | 2025-06-19 | — | — | WO | disclosed |
| CN-120157686-A | Compound with AKT kinase degradation activity, preparation method and pharmaceutical application thereof | 南京正大天晴制药有限公司 | 2025-06-17 | — | — | CN | disclosed |
| US-20250129091-A1 | THIENOPYRROLOTRIAZINE COMPOUNDS, THEIR PREPARATION AND THEIR THERAPEUTIC USE | SANOFI (FR) | 2025-04-24 | — | — | US | disclosed |
| EP-4522176-A1 | SELECTIVE DOPAMINE INCREASE | Sobrera Pharma AB (SE) | 2025-03-19 | — | — | EP | disclosed |
| EP-4499612-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2025-02-05 | — | — | EP | disclosed |
| US-12162893-B2 | Tricyclic pyridones and pyrimidones | ERASCA, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| CN-118974020-A | Substituted 3-aminoindazole derivatives as kinase inhibitors | 内尔维亚诺医疗科学公司 | 2024-11-15 | — | — | CN | disclosed |
| EP-4421068-A1 | NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Zhejiang Aixplorer Biotech Co., Ltd. (CN) | 2024-08-28 | — | — | EP | disclosed |
| CN-118459466-A | Triazolopyrimidinone derivative and application thereof in medicine | 西藏海思科制药有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-118339151-A | Compound for inhibiting or degrading BRD9, composition and pharmaceutical application thereof | 西藏海思科制药有限公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-3651762-B1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | UNIV VANDERBILT (US) | 2024-07-03 | — | — | EP | disclosed |
| CN-118063435-A | Piperidine-2, 6-dione derivative and application thereof | 西藏海思科制药有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-117946111-A | Aryl heterocycle Kv1.3 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20240043436-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2024-02-08 | — | — | US | disclosed |
| US-20240043421-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS INC (US) | 2024-02-08 | — | — | US | disclosed |
| EP-4301363-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | Nikang Therapeutics, Inc. (US) | 2024-01-10 | — | — | EP | disclosed |
| CN-117229263-A | Compound for inhibiting or degrading Bcl6 and application of compound in medicine | 四川海思科制药有限公司 | 2023-12-15 | — | — | CN | disclosed |
| WO-2023226950-A1 | PEPTIDOMIMETIC STAT PROTEIN DEGRADER, COMPOSITION AND USE THEREOF | 杭州和正医药有限公司 | 2023-11-30 | — | — | WO | disclosed |
| CN-117126231-A | Peptoid STAT protein degradation agent, composition and application thereof | 杭州和正医药有限公司 | 2023-11-28 | — | — | CN | disclosed |
| WO-2023219548-A1 | SELECTIVE DOPAMINE INCREASE | SOBRERA PHARMA AB (SE) | 2023-11-16 | — | — | WO | disclosed |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2023208165-A1 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2023-11-02 | — | — | WO | disclosed |
| CN-116969921-A | Compound for inhibiting or degrading HPK1 kinase and application thereof in medicine | 四川海思科制药有限公司 | 2023-10-31 | — | — | CN | disclosed |
| WO-2023186773-A1 | SUBSTITUTED 3-AMINO INDAZOLE DERIVATIVES AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2023-10-05 | — | — | WO | disclosed |
| CN-116710430-A | Methods and compounds for restoring mutant p53 function | 皮姆维制药公司 | 2023-09-05 | — | — | CN | disclosed |
| US-11718620-B2 | Method for treating a cancer mediated by abnormality of multi-kinases | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2023-08-08 | — | — | US | disclosed |
| CN-116554147-A | Pyrazole derivative, composition and pharmaceutical application thereof | 四川海思科制药有限公司 | 2023-08-08 | — | — | CN | disclosed |
| WO-2023143384-A1 | COMPOUND FOR INHIBITING OR DEGRADING HPK1 KINASE AND MEDICAL USE THEREOF | 四川海思科制药有限公司 | 2023-08-03 | — | — | WO | disclosed |
| WO-2023143370-A1 | NITROGEN-CONTAINING HETEROAROMATIC RING COMPOUND AS WELL AS COMPOSITION AND PHARMACEUTICAL USE THEREOF | 四川海思科制药有限公司 | 2023-08-03 | — | — | WO | disclosed |
| CN-116529248-A | Benzene ring derivative, composition and pharmaceutical application thereof | 四川海思科制药有限公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-112010858-B | BTK inhibitor, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2023-07-18 | — | — | CN | disclosed |
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
| CN-116375742-A | Azaaromatic ring derivative, composition and pharmaceutical application thereof | 海思科医药集团股份有限公司 | 2023-07-04 | — | — | CN | disclosed |
| WO-2023109892-A1 | COMPOUND FOR INHIBITING OR DEGRADING BRD9, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 海思科医药集团股份有限公司 | 2023-06-22 | — | — | WO | disclosed |
| US-20230183224-A1 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-06-15 | — | — | US | disclosed |
| CN-116253717-A | Pyridazine derivative and application thereof in medicine | 海思科医药集团股份有限公司 | 2023-06-13 | — | — | CN | disclosed |
| US-11655217-B2 | Pyrazole MAGL inhibitors | H. LUNDBECK A/S (DK) | 2023-05-23 | — | — | US | disclosed |
| CN-116134028-A | Compound capable of degrading BTK kinase, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2023-05-16 | — | — | CN | disclosed |
| WO-2023066377-A1 | NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 索智生物科技（浙江）有限公司 | 2023-04-27 | — | — | WO | disclosed |
| US-11634418-B2 | Amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2023-04-25 | — | — | US | disclosed |
| EP-4149459-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV Pharmaceuticals, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| WO-2023016518-A1 | HETEROCYCLIC DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 四川海思科制药有限公司 | 2023-02-16 | — | — | WO | disclosed |
| US-20230002403-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-11459315-B2 | Modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| WO-2022187528-A1 | QUINAZOLINE AMINE DERIVATIVES AS KRAS INHIBITORS | NIKANG THERAPEUTICS, INC (US) | 2022-09-09 | — | — | WO | disclosed |
| CN-114920690-A | Amide derivative and application thereof in medicine | 四川海思科制药有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-114874286-A | Compound for degrading BTK kinase, pharmaceutical composition and pharmaceutical application thereof | 四川海思科制药有限公司 | 2022-08-09 | — | — | CN | disclosed |
| WO-2022111526-A1 | BENZENE RING DERIVATIVE, AND COMPOSITION AND PHARMACEUTICAL USE THEREOF | 四川海思科制药有限公司 | 2022-06-02 | — | — | WO | disclosed |
| US-20220119409-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. | 2022-04-21 | — | — | US | disclosed |
| CN-112812100-B | Compound capable of degrading BTK kinase, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-114286820-A | Enzyme inhibitors | 卡尔维斯塔制药有限公司 | 2022-04-05 | — | — | CN | disclosed |
| CN-114075218-A | USP7 inhibitor | 首药控股(北京)股份有限公司 | 2022-02-22 | — | — | CN | disclosed |
| CN-108697710-B | Novel substituted cyanoindoline derivatives as NIK inhibitors | 杨森制药有限公司 | 2022-02-18 | — | — | CN | disclosed |
| US-20220048913-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2022-02-17 | — | — | US | disclosed |
| US-20220048913-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2022-02-17 | — | — | US | disclosed |
| WO-2022032484-A1 | PYRIDAZINE-3-FORMAMIDE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | 北京诺诚健华医药科技有限公司 | 2022-02-17 | — | — | WO | disclosed |
| US-11180487-B2 | Substituted cyanoindoline derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2021-11-23 | — | — | US | disclosed |
| WO-2021231474-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-11-18 | — | — | WO | disclosed |
| CN-113292536-A | Compound capable of degrading Bcr-Abl or PARP and preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-112812100-A | Compound capable of degrading BTK kinase, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2021-05-18 | — | — | CN | disclosed |
| US-20210087182-A1 | NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-03-25 | — | — | US | disclosed |
| CN-112390785-A | BET family bromodomain inhibitor ring derivative, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2021-02-23 | — | — | CN | disclosed |
| WO-2020239103-A1 | BTK INHIBITOR RING DERIVATIVE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL APPLICATION THEREOF | 四川海思科制药有限公司 | 2020-12-03 | — | — | WO | disclosed |
| CN-112010858-A | BTK inhibitor, preparation method and pharmaceutical application thereof | 四川海思科制药有限公司 | 2020-12-01 | — | — | CN | disclosed |
| US-20200308158-A1 | BEZOXAZINE DERIVATIVES USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2020-10-01 | — | — | US | disclosed |
| WO-2020163816-A1 | QUINOLIN-4-ONE AND 4(1H)-CINNOLINONE COMPOUNDS AND METHODS OF USING SAME | Frequency Therapeutics, Inc. (US) | 2020-08-13 | — | — | WO | disclosed |
| EP-3651762-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | Vanderbilt University (US) | 2020-05-20 | — | — | EP | disclosed |
| EP-3071566-B1 | NEW 1-(4-PYRIMIDINYL)-1H-PYRROLO[3,2-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-04-15 | — | — | EP | disclosed |
| CN-110891569-A | Antagonists of muscarinic acetylcholine receptor M4 | 范德堡大学 | 2020-03-17 | — | — | CN | disclosed |
| CN-110891569-A | Antagonists of muscarinic acetylcholine receptor M4 | 范德堡大学 | 2020-03-17 | — | — | CN | disclosed |
| WO-2019036377-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| US-10208056-B2 | Condensed tricyclic compounds as protein kinase inhibitors | Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) | 2019-02-19 | — | — | US | disclosed |
| WO-2019014427-A1 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY (US) | 2019-01-17 | — | — | WO | disclosed |
| EP-3405196-A1 | NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | Janssen Pharmaceutica NV (BE) | 2018-11-28 | — | — | EP | disclosed |
| CN-108697710-A | Novel substituted cyanoindoline derivatives as NIK inhibitors | 杨森制药有限公司 | 2018-10-23 | — | — | CN | disclosed |
| CN-106083704-B | Application of-two aryl methylene-N- cyclopropyl piperidine -4- ketone compounds of 3,5- (E) as Hsp90 inhibitor | 福建医科大学 | 2018-07-27 | — | — | CN | disclosed |
| US-9981957-B2 | Synthetic process | THE UNIVERSITY OF LIVERPOOL (GB) | 2018-05-29 | — | — | US | disclosed |
| US-9981963-B2 | 3-(1H-pyrazol-4-yl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| US-9981962-B2 | Pyrazole derivatives as NIK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-29 | — | — | US | disclosed |
| WO-2018013867-A1 | INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7) | MARINEAU JASON J (US) | 2018-01-18 | — | — | WO | disclosed |
| WO-2017125530-A1 | NEW SUBSTITUTED CYANOINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-27 | — | — | WO | disclosed |
| US-9708334-B2 | Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridine compounds as GlyT1 inhibitors | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2017-07-18 | — | — | US | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| EP-3049412-B1 | NEW 3-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-C]PYRIDINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-07-12 | — | — | EP | disclosed |
| EP-2693882-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME (US) | 2017-06-28 | — | — | EP | disclosed |
| CN-105051005-B | Cyclopropylamine compound and use thereof | 武田药品工业株式会社 | 2017-06-13 | — | — | CN | disclosed |
| WO-2017088738-A1 | MODIFIED COMPOUND OF ANDROGRAPHOLIDE | 南京明德新药研发股份有限公司 | 2017-06-01 | — | — | WO | disclosed |
| US-20170114070-A1 | INHIBITORS OF THE WNT SIGNALLING PATHWAYS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-04-27 | — | — | US | disclosed |
| US-20170107208-A1 | SYNTHETIC PROCESS | THE UNIVERSITY OF LIVERPOOL (GB) | 2017-04-20 | — | — | US | disclosed |
| US-20170066776-A1 | Novel substituted pyrimidine compounds | GRUENENTHAL GMBH (DE) | 2017-03-09 | — | — | US | disclosed |
| WO-2017033019-A1 | CONDENSED TRICYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS CARLOS III (CNIO) (ES) | 2017-03-02 | — | — | WO | disclosed |
| EP-3134406-A1 | SUBSTITUTED 2,4,5,6-TETRAHYDROPYRROLO[3,4-C]PYRAZOLE AND 4,5,6,7-TETRAHYDRO-2H-PYRAZOLO [4,3-C]PYRIDINE COMPOUNDS AS GLYT1 INHIBITORS | Dart Neuroscience (Cayman) Ltd (KY) | 2017-03-01 | — | — | EP | disclosed |
| US-20170044167-A1 | SUBSTITUTED 2,4,5,6-TETRAHYDROPYRROLO[3,4-C]PYRAZOLE AND 4,5,6,7-TETRAHYDRO-2H-PYRAZOLO[4,3-C]PYRIDINE COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE LLC | 2017-02-16 | — | — | US | disclosed |
| US-9540349-B2 | Substituted pyrimidine compounds | GRUENENTHAL GMBH (DE) | 2017-01-10 | — | — | US | disclosed |
| US-20160355488-A1 | TRIAZOLES FOR THE TREATMENT OF DEMYELINATING DISEASES | VERTEX PHARMACEUTICALS INCORPORATED | 2016-12-08 | — | — | US | disclosed |
| CN-106083704-A | 3,5 (E) two aryl methylene N cyclopropyl piperidine 4 ketone compounds is as the application of Hsp90 inhibitor | 福建医科大学 | 2016-11-09 | — | — | CN | disclosed |
| CN-103958465-B | Phenyl derivatives | 小野药品工业株式会社 | 2016-08-31 | — | — | CN | disclosed |
| US-20160016937-A1 | Novel substituted pyrimidine compounds | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| WO-2015164520-A1 | SUBSTITUTED 2,4,5,6-TETRAHYDROPYRROLO[3,4-C] PYRAZOLE AND 4,5,6,7-TETRAHYDRO-2H-PYRAZOLO [4,3-C] PYRIDINE COMPOUNDS AS GLYT1 INHIBITORS | DART NEUROSCIENCE, LLC (US) | 2015-10-29 | — | — | WO | disclosed |
| US-20150274664-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Marck Sharp & Dohme Corp. (US) | 2015-10-01 | — | — | US | disclosed |
| EP-2900242-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2015-08-05 | — | — | EP | disclosed |
| US-8957062-B2 | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2015-02-17 | — | — | US | disclosed |
| WO-2014052379-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-04-03 | — | — | WO | disclosed |
| US-8680273-B2 | Process for the preparation of piperazinyl and diazepanyl benzamide derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-25 | — | — | US | disclosed |
| US-20140057893-A1 | SUBSTITUTED CYCLOPROPLY COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2014-02-27 | — | — | US | disclosed |
| EP-2693882-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | Merck Sharp & Dohme Corp. (US) | 2014-02-12 | — | — | EP | disclosed |
| EP-2688890-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | Advinus Therapeutics Limited (IN) | 2014-01-29 | — | — | EP | disclosed |
| CN-101932577-B | Heteroaryl-substituted piperidines | BAYER HEALTHCARE AG | 2013-07-17 | — | — | CN | disclosed |
| CN-103012376-A | Amide derivatives | ASTRAZENECA AB | 2013-04-03 | — | — | CN | disclosed |
| US-20120309938-A1 | HEMIASTERLIN DERIVATIVES AND USES THEREOF IN THE TREATMENT OF CANCER | EISAI CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| WO-2012138845-A1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2012127506-A1 | SUBSTITUTED FUSED TRICYCLIC COMPOUNDS, COMPOSITIONS AND MEDICINAL APPLICATIONS THEREOF | ADVINUS THERAPEUTICS LIMITED (IN) | 2012-09-27 | — | — | WO | disclosed |
| EP-2175933-B1 | TRIAZINE KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-1851199-B1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | AVENTIS PHARMA INC (US) | 2012-05-16 | — | — | EP | disclosed |
| US-8143287-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110136766-A1 | AURORA KINASE INHIBITORS | VITAE PHARMACEUTICALS, INC. | 2011-06-09 | — | — | US | disclosed |
| EP-2125748-B1 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-7943768-B2 | Piperazine compounds useful as antagonists of C-C chemokines (Ccr2b and CcrS) for the treatment of inflammatory diseases | ASTRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-20110105752-A1 | PROCESS FOR THE PREPARATION OF PIPERAZINYL AND DIAZEPANYL BENZAMIDE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2011-05-05 | — | — | US | disclosed |
| CN-101932577-A | Heteroaryl-substituted piperidines | BAYER HEALTHCARE AG | 2010-12-29 | — | — | CN | disclosed |
| US-20100323965-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| EP-1797035-B1 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK SHARP & DOHME (US) | 2010-11-17 | — | — | EP | disclosed |
| US-7786159-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7776886-B2 | Cyclopropyl piperidine glycine transporter inhibitors | MERCK SHARP & DOHME CORP. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100104659-A1 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2010-04-29 | — | — | US | disclosed |
| EP-2146967-A2 | TETRAHYDROINDOLE AND TETRAHYDROINDAZOLE DERIVATIVES | Serenex, Inc. (US) | 2010-01-27 | — | — | EP | disclosed |
| US-7625889-B2 | Substituted bis aryl and heteroaryl compounds as selective 5HT2A antagonists | AVENTIS PHARMACEUTICALS INC. (US) | 2009-12-01 | — | — | US | disclosed |
| US-7618650-B2 | Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof | AVENTIS PHARMACEUTICALS INC (US) | 2009-11-17 | — | — | US | disclosed |
| EP-1928442-B1 | COMBINATION OF A HYPNOTIC AGENT AND SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUND AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMA INC (US) | 2009-11-04 | — | — | EP | disclosed |
| EP-2086551-A2 | THROMBOPOIETIN MIMETICS | Stategics, Inc. (US) | 2009-08-12 | — | — | EP | disclosed |
| EP-1797035-A4 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO INC (US) | 2009-08-05 | — | — | EP | disclosed |
| EP-2041141-A2 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-20080287453-A1 | Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| WO-2008130879-A2 | TETRAHYDROINDOLE AND TETRAHYDROINDAZOLE DERIVATIVES | SERENEX, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| US-20080269193-A1 | Tetrahydroindole and Tetrahydroindazole Derivatives | SERENEX, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080139621-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080138413-A1 | COMBINATION OF A HYPNOTIC AGENT AND SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUND AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008070583-A2 | THROMBOPOIETIN MIMETICS | STATEGICS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| EP-1928442-A2 | COMBINATION OF A HYPNOTIC AGENT AND SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUND AND THERAPEUTIC APPLICATION THEREOF | Aventis Pharmaceuticals Inc. (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20080108663-A1 | Cyclopropyl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME LLC | 2008-05-08 | — | — | US | disclosed |
| CN-100380530-C | Solid electrolyte, photoelectric converter and process for producing the same | SONY CORP (JP) | 2008-04-09 | — | — | CN | disclosed |
| WO-2008006883-A2 | BENZOPYRANOPYRAZOLES | 4SC AG (DE) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008005956-A2 | PYRROLOTRIAZINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-01-10 | — | — | WO | disclosed |
| US-20070265309-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1851199-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | Aventis Pharmaceuticals, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| CN-101031547-A | Cyclopropyl piperidine glycine transporter inhibitors | MERCK & CO INC (US) | 2007-09-05 | — | — | CN | disclosed |
| EP-1797035-A2 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | Merck & Co., Inc. (US) | 2007-06-20 | — | — | EP | disclosed |
| WO-2007024600-A2 | COMBINATION OF A HYPNOTIC AGENT AND SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUND AND THERAPEUTIC APPLICATION THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| EP-1712227-A1 | Amino diols useful in the treatment of Alzheimer's disease | Elan Pharmaceuticals, Inc. (US) | 2006-10-18 | — | — | EP | disclosed |
| WO-2006039221-A3 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO INC (US) | 2006-09-08 | — | — | WO | disclosed |
| WO-2006086705-A1 | SUBSTITUTED BIS ARYL AND HETEROARYL COMPOUNDS AS SELECTIVE 5HT2A ANTAGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006039221-A2 | CYCLOPROPYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2006-04-13 | — | — | WO | disclosed |
| CN-1653558-A | Solid electrolyte, photoelectric device and method for manufacturing the same | SONY CORP (JP) | 2005-08-10 | — | — | CN | disclosed |
| US-20050080141-A1 | Amino diols useful in the treatment of alzheimer's disease | SCHOSTAREZ HEINRICH J (US) | 2005-04-14 | — | — | US | disclosed |
| US-20040220272-A1 | Propargyl glycine amino propargyl diol compounds for treatment of hypertension | G.D. SEARLE & CO. | 2004-11-04 | — | — | US | disclosed |
| EP-1448177-A1 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-6777572-B2 | PROPARGYL GLYCINE AMINO PROPARGYL DIOL DERIVATIVES ARE USEFUL AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION. | PHARMACIA CORPORATION (OF PFIZER INC.) | 2004-08-17 | — | — | US | disclosed |
| US-6667414-B2 | Renin inhibitors; hypertensive agents | PHARMACIA CORPORATION | 2003-12-23 | — | — | US | disclosed |
| US-20030144542-A1 | Use of propargyl glycine amino propargyl diol compounds for treatment of renal failure | HANSON GUNNAR J (US) | 2003-07-31 | — | — | US | disclosed |
| US-20030135066-A1 | Use of propargyl glycine amino propargyl diol compounds for treatment of congestive heart failure | HANSON GUNNAR J (US) | 2003-07-17 | — | — | US | disclosed |
| US-20030130522-A1 | Use of propargyl glycine amino propargyl diol compounds for prevention of hypertension | HANSON GUNNAR J (US) | 2003-07-10 | — | — | US | disclosed |
| WO-2003043618-A2 | AMINO DIOLS USEFUL IN THE TREATMENT OF ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-05-30 | — | — | WO | disclosed |
| US-6515025-B2 | Renin inhibitor | PHARMACIA CORPORATION | 2003-02-04 | — | — | US | disclosed |
| US-20020025934-A1 | Ethynyl alanine amino diol compounds for treatment of hypertension | G.D. SEARLE & CO. (US) | 2002-02-28 | — | — | US | disclosed |
| US-6342624-B1 | INHIBITION OF ENZYMES WITH PEPTIDES | G. D. SEARLE & CO. | 2002-01-29 | — | — | US | disclosed |
| US-6281235-B1 | CONTROL OF HYPERTENSION. | G.D. SEARLE & CO. | 2001-08-28 | — | — | US | disclosed |
| US-6174923-B1 | ADMINISTERING ETHYNYL ALANINE AMINO DIOL COMPOUND FOR TREATING HYPERTENSION | G. D. SEARLE & CO. | 2001-01-16 | — | — | US | disclosed |
| US-5942548-A | ACT AS RENIN INHIBITORS; ADMINISTERING TO TREAT CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1999-08-24 | — | — | US | disclosed |
| US-5849773-A | Amino acyl amino propargyl diol compounds for treatment of hypertension | G. D. SEARLE & CO. (US) | 1998-12-15 | — | — | US | disclosed |
| US-5508295-A | RENIN INHIBITORS | G. D. SEARLE & CO. (US) | 1996-04-16 | — | — | US | disclosed |
| US-5484811-A | ADMINISTERING A RENIN INHIBITOR TO A SUBJECT | G. D. SEARLE & CO. (US) | 1996-01-16 | — | — | US | disclosed |
| US-5484812-A | ADMINISTERING A RENIN INHIBITOR TO A SUBJECT | G.D. SEARLE & CO. (US) | 1996-01-16 | — | — | US | disclosed |
| EP-0610451-A1 | ETHYNYL ALANINE AMINO DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1994-08-17 | — | — | EP | disclosed |
| US-5330996-A | Renin inhibitors | G. D. SEARLE & CO. (US) | 1994-07-19 | — | — | US | disclosed |
| US-5227401-A | ETHYNYL ALANINE AMINO DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G. D. SEARLE & CO. (US) | 1993-07-13 | — | — | US | disclosed |
| US-5223535-A | Renin inhibitors | G. D. SEARLE & CO. (US) | 1993-06-29 | — | — | US | disclosed |
| WO-1993009108-A1 | AMINO ACYL AMINO PROPARGYL DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1993-05-13 | — | — | WO | disclosed |
| WO-1993009086-A1 | PROPARGYL GLYCINE AMINO PROPARGYL DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1993-05-13 | — | — | WO | disclosed |
| WO-1993009087-A1 | ETHYNYL ALANINE AMINO DIOL COMPOUNDS FOR TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1993-05-13 | — | — | WO | disclosed |
| EP-0539976-A1 | Ethynyl-alanine-amino-diol compounds for treatment of hypertension | G.D. Searle & Co. (US) | 1993-05-05 | — | — | EP | disclosed |
| EP-0539976-A1 | Ethynyl-alanine-amino-diol compounds for treatment of hypertension | G.D. Searle & Co. (US) | 1993-05-05 | — | — | EP | disclosed |